Qureight and Remedy Cell have collaborated to validate the mechanism of action of RC-0315 in the Phase Ib clinical trial for treating idiopathic pulmonary fibrosis (IPF). The trial’s primary objective ...
The U.S. Multi-Society Task Force on Colorectal Cancer has released updated guidance establishing a “reasonable benchmark” ...